SCHEMBL2477468

SCHEMBL2477468

NC(=O)c1cnc(Nc2ccc(OCCO)cc2)cc1NCc1cc(F)cc(F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 14/20 0.58
▸ IRAK4 Q9NWZ3 9/20 0.58
▸ JAK2 O60674 5/20 0.58
▸ JAK1 P23458 5/20 0.58
▸ TYK2 P29597 4/20 0.58
▸ CSF1R P07333 1/20 0.48
▸ BTK Q06187 1/20 0.48
▸ STAT6 P42226 1/20 0.45
▸ STAT3 P40763 1/20 0.41
▸ AURKA O14965 1/20 0.40
▸ RPS6KB1 P23443 1/20 0.40
▸ AURKB Q96GD4 1/20 0.40
▸ CLK1 P49759 1/20 0.38
▸ CDC7 O00311 1/20 0.38
▸ ROCK2 O75116 1/20 0.38
▸ MAP4K4 O95819 1/20 0.38
▸ PIM1 P11309 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ CLK4 Q9HAZ1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12301531 0.91 JAK3 (0.57) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2483656 0.90 JAK3 (0.56) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2478885 0.88 JAK3 (0.62) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2482789 0.86 JAK3 (0.58) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2485607 0.86 JAK3 (0.76) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2476310 0.86 JAK3 (0.65) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2479526 0.85 JAK3 (0.59) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL12301734 0.85 JAK3 (0.64) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL12301505 0.85 JAK3 (0.64) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL12301740 0.84 JAK3 (0.80) JAK3IRAK4JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 — — US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 — — US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 — — US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 — — EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 — — EP disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 — — US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA JAK3 1/4885IRAK4 128/4885JAK2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback